reports
- Sean Conroy
Cereno Scientific - CS014 (thrombosis) progresses towards the clinic
Cereno Scientific has taken a step closer to advancing its second asset, CS014, a novel HDAC inhibitor with epigenetic effects, to the clinic with the submission of the clinical trial application (CTA) to the European Medicines Agency (EMA). The CTA is for the first-in-human Phase I trial for CS014, which Cereno is developing for thrombosis prevention, without increased risk of bleeding. We believe this has the potential to address the main limitation of current standard-of-care antithrombotic m...
Edison issues initiation on Cereno Scientific (CRNO B): Differentiated...
Edison Investment Research Limited Edison issues initiation on Cereno Scientific (CRNO B): Differentiated approach in CVD with potential 22-Feb-2024 / 12:36 GMT/BST The issuer is solely responsible for the content of this announcement. London, UK, 22 Februar 2024 Edison issues initiation on Cereno Scientific (CRNO B): Differentiated approach in CVD with potential Cereno Scientific is a clinical-stage biotech, developing treatments for cardiovascular diseases (CVDs) using novel approaches. Its focus on disease-modifying therapies and a collaboration with Abbott set it apart f...
- Sean Conroy
Cereno Scientific - Differentiated approach in CVD with potential
Cereno Scientific is a clinical-stage biotech, developing treatments for cardiovascular diseases (CVDs) using novel approaches. Its focus on disease-modifying therapies and a collaboration with Abbott set it apart from peers. Lead asset CS1, a delayed immediate release formulation of VPA, is an HDAC inhibitor, aiming to deliver disease-modifying results in pulmonary arterial hypertension (PAH). Preclinical candidates include CS014, for thrombosis prevention without increased risk of bleeding (se...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.